TrialBritish journal of haematology2026

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.

Sosana Delimpasi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.